Erasca, Inc.

Equities

ERAS

US29479A1088

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 09:55:44 09/05/2024 pm IST			5-day change	1st Jan Change
2.095 ^USD	-2.56%		-2.56%	-1.64%

08/05	Erasca, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03/04	North American Morning Briefing : Powell Awaited -2-	DJ

Erasca, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023

March 28, 2024 at 01:31 am IST

Erasca, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 29.7 million compared to USD 135.25 million a year ago. Basic loss per share from continuing operations was USD 0.2 compared to USD 1.06 a year ago.

Latest news about Erasca, Inc.

Erasca, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
North American Morning Briefing : Powell Awaited -2-	03/04	DJ
Goldman Sachs Adjusts Erasca's Price Target to $7 From $6, Maintains Buy Rating	02/04	MT
Erasca, Inc. announced that it has received $45 million in funding	02/04	CI
Erasca, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
Erasca, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/03	CI
Erasca, Inc. announced that it expects to receive $45 million in funding	27/03	CI
Capital One Initiates Erasca at Overweight Rating With $8 Price Target	11/03	MT
Erasca Enters Two Supply Deals With Novartis for Trametinib	14/02	MT
Erasca, Inc. Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials	14/02	CI
North American Morning Briefing : Boeing Drags -2-	08/01	DJ
Erasca, Inc. Receives FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma	11/12	CI
ErascaCEO Bought Shares Worth $1,696,179, According to a Recent SEC Filing	07/12	MT
HC Wainwright Cuts Erasca Price Target to $8 From $10, Maintains Buy Rating	28/11	MT
Erasca Completes Dose Escalation in Phase 1 Thunderbbolt-1 Trial; Extends Cash Runway to 2026	28/11	MT
Erasca, Inc. Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway	28/11	CI
Erasca, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
HC Wainwright Initiates Erasca at Buy Rating With $10 Price Target	11/23/11	MT
Erasca Shares Jump After CEO Stock Purchase Disclosed	10/23/10	MT
Erasca Insider Bought Shares Worth $2,026,000, According to a Recent SEC Filing	10/23/10	MT
Erasca Doses First Patient in Trial Assessing Naporafenib Plus Trametinib in Patients With RAS Q61X Solid Tumors	29/23/29	MT
Erasca, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
Erasca, Inc.(NasdaqGS:ERAS) added to Russell 3000E Index	23/23/23	CI
Erasca, Inc.(NasdaqGS:ERAS) added to Russell Microcap Index	23/23/23	CI
Erasca, Inc.(NasdaqGS:ERAS) added to Russell Microcap Value Index	23/23/23	CI

Chart Erasca, Inc.

Duration

Period

More charts

Company Profile

Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled a wholly owned or controlled RAS/MAPK pathway-focused pipeline in the industry, which is focused on modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes three clinical-stage programs, such as a pan-RAF inhibitor, an ERK inhibitor, and a central nervous system (CNS)-penetrant EGFR inhibitor, and additional discovery-stage programs targeting other key oncogenic drivers. Its lead product candidate is naporafenib, a pan-RAF inhibitor with the potential for patients with NRAS-mutated (NRASm) melanoma, RAS Q61X solid tumors, and other RAS/MAPK pathway-driven tumors.

Sector

Biotechnology & Medical Research

Calendar

09/05/2024 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.15 USD

Average target price

7 USD

Spread / Average Target

+225.58%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ERASCA, INC.	-1.64%	325M
MODERNA, INC.	+25.07%	46.71B
LONZA GROUP AG	+48.83%	41.8B
IQVIA HOLDINGS INC.	-1.20%	41.52B
CELLTRION, INC.	-3.42%	29.55B
ICON PUBLIC LIMITED COMPANY	+10.44%	25.78B
ALNYLAM PHARMACEUTICALS, INC.	-21.06%	19.26B
BIO-TECHNE CORPORATION	+1.70%	12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.45%	12.08B
MEDPACE HOLDINGS, INC.	+27.26%	11.98B

Other Biotechnology & Medical Research